While an FDA panel recommended approval of Sprout Pharmaceuticals Inc.’s female sexual dysfunction drug Addyi (flibanserin), several members conditioned their vote on a labeling contraindication and a Risk Evaluation and Mitigation Strategy, despite uncertainties that either would be able to prevent the alcohol use that exacerbates adverse events.
At a joint June 4 meeting, FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 18-6 in favor of approval of flibanserin...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?